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The basics of 
bipolar disorder 
When diagnosing a young person with bipolar disorder, practitioners need to use 
standardized criteria such as those outlined in 
the Diagnostic and Statistical Manual of Mental 
Disorders-5 or the International Classification 
of Diseases-11.1–2 Two types of disorder are 
recognized: bipolar I, which is more serious, 
and bipolar II.
To be diagnosed with bipolar I, a young 
person must have experienced a distinct manic 
episode involving both the following symptoms 
most of the day and nearly every day for seven 
days or more:
t 1FSTJTUFOUMZBOEBCOPSNBMMZFMFWBUFEFYQBOTJWFPSJSSJUBCMFNPPEand 
t 1FSTJTUFOUMZBOEBCOPSNBMMZJODSFBTFEFOFSHZBOEBDUJWJUZ1
As well, at least three of the following symptoms must be present to a significant degree 
and must represent a marked change from the young person’s usual presentation:
t *OìBUFETFMGFTUFFN
t %FDSFBTFEOFFEGPSTMFFQ
t *ODSFBTFEUBMLJOHPSQSFTTVSFETQFFDI
t 3BDJOHUIPVHIUT
t %JTUSBDUJCJMJUZ
t *ODSFBTFEHPBMEJSFDUFEBDUJWJUJFTPSQTZDIPNPUPSBHJUBUJPO
t &YDFTTJWFJOWPMWFNFOUJOBDUJWJUJFTXJUIIJHIQPUFOUJBMGPSOFHBUJWFPVUDPNFT	FHUBLJOHSJTLT
1
ɨFNPPEEJTUVSCBODFNVTUCFTFWFSFFOPVHIUPNBSLFEMZBêFDUUIFZPVOHQFSTPOTGVODUJPOJOH1TZDIPTJT
NBZBMTPEFWFMPQ'VSUIFSUIFJOìVFODFPGTVCTUBODFTPSBNFEJDBMDPOEJUJPONVTUBMTPCFSVMFEPVU/PUF
that while some young people with bipolar disorder experience major depressive episodes, they are not 
required for a diagnosis of bipolar I.
To be diagnosed with bipolar II, in comparison, a young person must meet criteria for a “hypomanic” 
episode and for a major depressive episode.1 A hypomanic episode is identical to a manic episode except that it 
lasts only four days rather than seven.1	1MFBTFTFFUIFFall 2017 Quarterly for more information on diagnosing 
NBKPSEFQSFTTJWFEJTPSEFS

Resolving controversies
Significant controversies about bipolar disorder in children began in the 1990s, when dramatic increases in 
diagnoses fuelled questions and debates.3–4 Since then, however, the controversy has waned. This waning has 
been due, in part, to research illuminating the likely cause for the diagnostic increases. Specifically, a review 
of diagnostic rates between 1985 and 2007 found that presumed prevalence increases did not indicate a 
Bipolar disorder is very rare in young people — below 1%.
Significant 
controversies about 
bipolar disorder in 
children began in the 
1990s.
oV E R V I E W
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SFBMJODSFBTFJOQSFWBMFODF3BUIFSUIFZNBJOMZSFìFDUFEUIFGBDUUIBUQSFWJPVTMZZPVOHQFPQMFXFSFSBSFMZ
diagnosed with bipolar disorder.4 More recent data from nearly 200 countries continue to show that bipolar 
disorder is very rare in young people — below 1%.5
Why comprehensive assessment remains critical
Still, bipolar disorder continues to be a condition that is susceptible to both overdiagnosis and 
underdiagnosis.4 Both situations can cause harm. Overdiagnosis can lead to the prescription of unnecessary 
medications as well as negative labelling and stigma. Conversely, underdiagnosis can result in children not 
HFUUJOHIFMQXIFOUIFZOFFEJU1SBDUJUJPOFSTUIFSFGPSFOFFEUPCFQBSUJDVMBSMZDBSFGVMXIFOBTTFTTJOHDIJMESFO
for bipolar disorder.
1SBDUJUJPOFSTBMTPOFFEUPCFQSFQBSFEJGZPVOHQFPQMFPSQBSFOUTDBSFHJWFSTSBJTFUIF
issue of bipolar disorder. For example, they may express concern about mood swings. Yet 
DBSFGVMRVFTUJPOJOHDPVMEMFBEUPPUIFSFYQMBOBUJPOTΉTVDIBTiNPPETXJOHTwSFìFDUJOH
UZQJDBMNPPEWBSJBUJPOTGPSBEPMFTDFOUTPSSFìFDUJOHSFBDUJPOTUPTUSFTTPSTPSBEWFSTF
experiences. 
The typical age of onset for bipolar disorder provides another reason for being 
particularly cautious before making a diagnosis. For bipolar I, the average age of onset for a 
manic, hypomanic or major depressive episode is about 18 years.1 This suggests that younger children are far 
less likely to meet diagnostic criteria for bipolar disorder. 
Following careful and comprehensive assessment, when young people do have bipolar disorder, effective 
treatments are critical. In the 3FWJFXBSUJDMF that follows, we identify effective interventions for these young 
people, including new psychosocial interventions.
overv iew
Effective treatments are critical when a young person has bipolar disorder.
Practitioners need 
to be particularly 
careful when assessing 
children for bipolar 
disorder.
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Effective treatments 
for bipolar disorder
Young people who have bipolar disorder need effective treatment options. To identify UIFCFTUPQUJPOTXFSFWJFXFEIJHIRVBMJUZ
intervention studies published over the past two 
decades — including evidence on new psychosocial 
treatments. 
To identify interventions, we conducted a 
systematic review. We built quality assessment into 
our inclusion criteria to ensure that we reported on 
the best research available. In particular, we required 
all studies to measure core bipolar symptoms, 
namely mania or hypomania, and to use randomized 
controlled trial	3$5
FWBMVBUJPONFUIPET8FUIFO
TFBSDIFEGPS3$5TFWBMVBUJOHJOUFSWFOUJPOTGPSDIJMEIPPECJQPMBSEJTPSEFSQVCMJTIFEJOUIFQBTUΉZFBST8F
also reviewed previous Quarterly issues to identify older studies that met our current inclusion criteria. This 
QSPDFTTFOBCMFEVTUPBEESFTTUIFCFTU3$5FWJEFODFGSPNUIFQBTUΉZFBST	1MFBTFTFFUIFMethods section 
GPSNPSFEFUBJMTPOPVSTFBSDITUSBUFHZBOEJODMVTJPODSJUFSJB

8FSFUSJFWFEBOEFWBMVBUFEΉTUVEJFT5XFMWF3$5TNFUPVSJODMVTJPODSJUFSJBPGUIFTFTJYBTTFTTFE
medications, five assessed psychosocial interventions, and one assessed a dietary supplement. Five 
medications were evaluated in six trials: aripiprazole,6 asenapine,7MJUIJVN	UXP3$5T
8–9 quetiapine 
	BEKVODUJWFUPEJWBMQSPFYBOFYUFOEFESFMFBTFGPSNPGWBMQSPJDBDJE
10 and risperidone.11 Three psychosocial 
JOUFSWFOUJPOTXFSFFWBMVBUFE	UZQJDBMMZBEKVODUJWFUPNFEJDBUJPO
JOëWFUSJBMT.VMUJGBNJMZ1TZDIPFEVDBUJPOBM
1TZDIPUIFSBQZ	.'1&1
12$IJMEBOE'BNJMZ'PDVTFE$PHOJUJWF#FIBWJPVSBMɨFSBQZ	$''$#5
13 and 
'BNJMZ'PDVTFEɨFSBQZ	UISFF3$5T
14–16 Flax oil, a dietary supplement, was evaluated in one trial.17 Given 
the focus of our review, we limited our reporting to outcomes associated with bipolar disorder symptoms and 
related overall functioning, including quality of life.
Medication studies
*OëWFPGUIFTJYNFEJDBUJPO3$5TBMMDIJMESFOXFSF
EJBHOPTFEXJUICJQPMBSEJTPSEFS*OΉUIFPUIFS3$5
XFSFEJBHOPTFEXJUICJQPMBSEJTPSEFSUIFSFTU
were diagnosed with major depressive disorder and 
deemed at risk for bipolar disorder, because, for 
example, they had exhibited bipolar symptoms after 
using an antidepressant.8 All youth in this other study 
also had a secondary substance use disorder.
ɨF3$5TWBSJFEJOUIFJSEPTJOHBQQSPBDIFT
For aripriprazole and asenapine, dosing was fixed.6–7 
For lithium, quetiapine and risperidone, dosing was 
ìFYJCMFWBSZJOHXJUIUIFSBQFVUJDSFTQPOTF8‒11 As well, 
aripiprazole and risperidone were tested at two 
R E V I E W
Parents play an essential role in supporting young people with 
bipolar disorder. 
Translating drug names
Most medications are available in both generic and proprietary versions. Here we list the names that the drugs are sold 
under in Canada, if available.
 
Brand name
Abilify
Saphris
Not applicable
Latuda
Risperdal
Seroquel 
Generic name 
Aripiprazole*
Asenapine**
Lithium*
Lurasidone
Risperidone
Quetiapine
Medication class 
Atypical antipsychotic
Atypical antipsychotic
Mood stabilizer
Atypical antipsychotic
Atypical antipsychotic
Atypical antipsychotic
* Approved by Health Canada for the treatment of bipolar disorder in youth.
** Not available for sale in Canada. 
Bipolar Medications18
Chi ldren ’s  Menta l  Heal th  Research Quar ter ly  Vol .  13 ,  No.  1    6    © 2019 Children’s Health Policy Centre, Simon Fraser University
different doses and asenapine was tested at three different doses.6–7, 11 
'PSUIFRVFUJBQJOF3$5NFBOXIJMFCPUIJOUFSWFOUJPOBOEDPOUSPM
groups received divalproex, because researchers were evaluating 
quetiapine adjunctively to this medication.10	'PSXIZUIFZEJETP
TFFUIFTJEFCBSBUMFGU
"MMΉNFEJDBUJPOTXFSFDPNQBSFEUPQMBDFCP
/PUBCMZQIBSNBDFVUJDBMDPNQBOJFTXFSFJOWPMWFEJOBMMUIF
NFEJDBUJPO3$5TJODMVEJOHDPNQBOJFTQSPWJEJOHNFEJDBUJPOTGPS
the study, or study authors working for or holding stocks in the 
DPNQBOJFT1IBSNBDFVUJDBMDPNQBOJFTIBEFWFOHSFBUFSJOWPMWFNFOU
JOUXP3$5TɨJTJOWPMWFNFOUJODMVEFEQSPWJEJOHXSJUJOHBOE
editorial support for the risperidone trial, and providing direct 
oversight and participating throughout the asenapine trial.7, 11 The 
second lithium trial stood out as being the only one not funded 
CZBESVHDPNQBOZIPXFWFSTPNFBVUIPSTPOUIJTUSJBMTUJMMIBE
pharmaceutical company affiliations.9 Table 1 summarizes the 
NFEJDBUJPO3$5T
rev iew
 
Table 1: Medication Studies 
Ages (Years)
10 –17
10 –17 
12 –18 
7 –17 
12 –18 
10 –17 
Sample size
296 
404 
25
81
30
169 
Dose* and duration** 
10 or 30 mg for 4 weeks 
5, 10 or 20 mg for 3 weeks 
600 — 2,400 mg for 6 weeks 
600 — 3,600 mg for 8 weeks 
50 — 450 mg for 6 weeks
0.5 — 2.5 mg or 3 — 6 mg for 3 weeks
  
Medication
Aripiprazole 6
Asenapine 7
Lithium I 8
Lithium II 9
Quetiapine† 10
Risperidone 11
* Doses reflect daily total, with some being given in single and others in multiple doses. As well, doses are not comparable among medications.
** Duration includes total time on medication regardless of dose. In many studies, dose was titrated over time.
† Young people in both quetiapine and placebo groups received divalproex as the primary medication. 
Country
United States
United States + Russia
United States
United States
United States
United States
 
      
Psychosocial studies
We identified five new studies assessing psychosocial interventions, typically adjunctive to medications, 
GPSCJQPMBSEJTPSEFSJOZPVOHQFPQMF*OΉUISFFPGUIFëWF3$5TΉBTTFTTJOH$IJMEBOE'BNJMZ'PDVTFE
$#5	$''$#5
BOE'BNJMZ'PDVTFEɨFSBQZΉ*BOE***ΉBMMQBSUJDJQBOUTXFSFEJBHOPTFEXJUICJQPMBS
disorder.13–14, 16*OΉUIF3$5BTTFTTJOH.VMUJGBNJMZ1TZDIPFEVDBUJPOBM1TZDIPUIFSBQZ	.'1&1
IBE
bipolar disorder while the others had depression or dysthymia.12*OΉUIF3$5BTTFTTJOH'BNJMZ'PDVTFE
ɨFSBQZΉ**IBECJQPMBSEJTPSEFSXIJMFUIFPUIFSTIBEEFQSFTTJPOPSDZDMPUIZNJB	XIJDIJOWPMWFTNVMUJQMF
periods of hypomanic symptoms and depressive symptoms that do not meet criteria for either hypomanic or 
EFQSFTTJWFFQJTPEFT
15
The psychosocial interventions all contained similar content. In particular, they provided education about 
bipolar disorder and taught skills to young people and their parents, including managing mood symptoms, 
QSPCMFNTPMWJOHBOEDPNNVOJDBUJOHTUSBUFHJFT12–16, 18&YBNQMFTPGTQFDJëDJOUFSWFOUJPOTJODMVEFEUFBDIJOH
BCPVUUIFDPOOFDUJPOCFUXFFOUIPVHIUTGFFMJOHTBOEBDUJPOTQSBDUJTJOHBDUJWFMJTUFOJOHBOEHFOFSBUJOH
solutions to problems and evaluating the pros and cons of each.12, 15
Why did researchers study 
quetiapine adjunctively?
Researchers assessed the effectiveness of quetiapine as an adjunctive treatment to 
divalproex after reviewing data from some 
less rigorous studies which found that while 
divalproex helped some young people, many 
still failed to respond to it.10 These researchers 
wanted to determine whether adding an atypical 
antipsychotic (quetiapine) to a mood stabilizer 
(divalproex) decreased manic symptoms and 
improved response rates.10 Notably, we could 
not find any high-quality evidence supporting 
the use of divalproex for treating bipolar disorder 
in young people. Although we did assess six 
randomized controlled trials evaluating valproic 
acid and its derivatives, including divalproex, 
none met our inclusion criteria. 
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However, intensity of the interventions varied considerably, as they ranged from 12 to 21 sessions. 
ɨFDPNQBSJTPOHSPVQTBMTPWBSJFESBOHJOHGSPNBXBJUMJTUDPOUSPMHSPVQGPS.'1&1USFBUNFOUBTVTVBM
	ΉVOTUSVDUVSFETFTTJPOT
GPS$''$#5BOEGBNJMZFEVDBUJPOTFTTJPOTGPS'BNJMZ'PDVTFEɨFSBQZ	UISFF
GPSWFSTJPOTΉ*BOE***BOEPOFPSUXPGPSWFSTJPOΉ**
.PTUZPVOHQFPQMFJOUIFQTZDIPTPDJBM3$5TXFSFBMTP
taking medications for their bipolar disorder — in both the intervention and comparison groups. Table 2 
TVNNBSJ[FTUIFQTZDIPTPDJBM3$5T
rev iew
 
Table 2: Psychosocial Intervention Studies 
Ages (Years) 
Country
8 –11 
United States
7 –13 
United States
12 –17 
United States
9 –17 
United States
12 –18 
United States
Sample  
size
166
 
69
 
58
 
40
 
145
Delivery
 
8 parent + 8 youth sessions* over 8 weeks
 
6 family sessions, 3 parent sessions + 3 youth 
sessions + 6 booster sessions** over 9 months 
21 family sessions over 9 months† 
 
12 family sessions over 4 months†
 
21 family sessions over 9 months† 
   
Program
 
Multifamily Psychoeducational 
Psychotherapy (MF-PEP)12
Child- and Family-Focused Cognitive- 
Behavioural Therapy (CFF-CBT)13
Family-Focused Therapy I 14
 
Family-Focused Therapy II 15
 
Family-Focused Therapy III 16
* Both parent and youth sessions used a group format. Each session began and ended with parent and youth together.
** Format of booster sessions varied according to families’ individual goals.
† Families could request additional sessions as needed.    
Dietary supplement study
8FBMTPBDDFQUFEPOFTUVEZPOBEJFUBSZTVQQMFNFOU*OΉUIJTìBYPJM3$5BMMQBSUJDJQBOUTXFSFEJBHOPTFEXJUI
bipolar disorder.17	ɨFBVUIPSTDIPTFUPFWBMVBUFìBYPJMCFDBVTFJUDPOUBJOTBMQIBMJOPMFOJDBDJEXIJDIUIFZ
IZQPUIFTJ[FENJHIUTUBCJMJ[FNPPE
%PTJOHXBTUJUSBUFETPZPVOHQFPQMFDPVMESFDFJWFVQUPΉHSBNT	PS
ΉN-
PGìBYPJMQFSEBZEVSJOHUIFXFFLUSJBM17ɨFDPOUSPMXBTPMJWFPJM"QQSPYJNBUFMZUXPUIJSETPG
QBSUJDJQBOUTXFSFBMTPCFJOHQSFTDSJCFENFEJDBUJPOTGPSUIFJSCJQPMBSEJTPSEFS5BCMFΉTVNNBSJ[FTUIJT3$5
 
Table 3: Dietary Supplement Study 
Ages (Years)
6 –17
Sample size
51 
Dose and duration 
Up to 12 grams (12.9 mL) for 16 weeks 
Supplement 
Flax oil 17
Country
United States
Medication outcomes
Aripiprazole was tested at doses of 10 mg and 30 mg daily. Both doses significantly reduced bipolar severity.6 
#PUIEPTFTBMTPSFEVDFENBOJDTZNQUPNTBDDPSEJOHUPDIJMEQBSFOUBOEDMJOJDJBOPCTFSWFSSFQPSUT*OΉGBDU
45% of those taking 10 mg of aripiprazole and 64% taking 30 mg experienced reductions of 50% or more in 
manic symptoms by observer report, compared with 26% for controls. But the medication had no impact on 
EFQSFTTJPOΉooXJUIPOFFYDFQUJPO1BSFOUSFQPSUFEEFQSFTTJPOTZNQUPNTXFSFTJHOJëDBOUMZSFEVDFEGPSUIPTF
UBLJOHΉNHEBJMZ	CVUOPUGPSUIPTFUBLJOHΉNH
'JOBMMZZPVOHQFPQMFTPWFSBMMGVODUJPOJOHTJHOJëDBOUMZ
improved on both aripiprazole doses, yet no differences were found for measures of quality of life compared  
to controls. 
"TFOBQJOFXBTUFTUFEBUUISFFEJêFSFOUEBJMZEPTFT	JFΉNHΉNHBOEΉNH
"MMUISFFEPTFT
significantly reduced bipolar severity and reduced manic symptoms by observer reports.7 Specifically, 42% of 
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youth on the 2.5 mg dose, 54% on 5 mg and 52% 
on 10 mg experienced reductions of 50% or more 
in manic symptoms, compared to only 28% of 
controls. 
#PUIMJUIJVN3$5TQSPEVDFENJYFESFTVMUT
In the lithium I trial, there was no difference on 
a combined measure of manic and depressive 
symptoms for young people taking lithium or 
placebo.8 However, participants taking lithium had 
better overall functioning than controls. 
In comparison, in the lithium II trial, this 
medication resulted in fewer manic symptoms 
compared with placebo.9 These findings included 
SFEVDFEPWFSBMMNBOJDTZNQUPNT	XJUINPEFSBUFeffect sizeCohen’s d = 0.53
BTXFMMBTNBOJDTZNQUPN
JNQSPWFNFOU	XJUIPGUIPTFPOMJUIJVNCFJOHSBUFEBTWFSZNVDIPSNVDIJNQSPWFEDPNQBSFEXJUI
POMZPGDPOUSPMT
)PXFWFSMJUIJVNEJEOPUTJHOJëDBOUMZPVUQFSGPSNQMBDFCPSFHBSEJOHNBOJDTFWFSJUZ
depressive symptoms or overall functioning. 
Quetiapine used adjunctively with divalproex showed one relevant benefit. The two 
medications together significantly reduced manic symptoms when compared with placebo 
plus divalproex.10 In fact, 87% of those taking both medications experienced reductions 
of 50% or more in manic symptoms, compared with only 53% of those on placebo plus 
divalproex. However, there was no difference between the groups regarding depressive 
symptoms or overall functioning.
'JOBMMZSJTQFSJEPOFTIPXFECFOFëUTBUCPUIMPXFSBOEIJHIFSEPTFSBOHFT	JFUP
ΉNHBOEΉUPΉNHUPUBMEBJMZEPTF
#PUISBOHFTTJHOJëDBOUMZSFEVDFECJQPMBSTFWFSJUZ
and manic symptoms.11 Specifically, 59% of those on lower doses and 63% on higher doses experienced 
reductions of 50% or more in manic symptoms, compared with only 26% for controls. There was, however, 
no difference between the groups for depressive symptoms.11
rev iew
Researchers have 
made progress 
in identifying 
interventions to help 
young people with 
bipolar disorder. 
What medications has the Canadian 
government approved?
Health Canada is the federal government agency that approves all drugs for use in Canada and indicates the approved terms 
of their use. Among the five medications we evaluated, only 
two are approved for treating bipolar disorder in young people. 
Aripiprazole is approved for treating manic or mixed episodes 
for 13- to 17-year-olds.18 And lithium is approved for treating 
manic episodes for those aged 12 years and older.18 In contrast, 
Health Canada specifically states that asenapine, risperidone and 
quetiapine are not indicated for use in people younger than 18. 
(Divalproex, another medication used in the trials we assessed,  
is also not approved for use in people younger than 18.) 
There are now promising new psychosocial treatments for bipolar disorder. 
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rev iew
5BCMFΉTVNNBSJ[FTUIFPVUDPNFTGPSBMMTJYNFEJDBUJPO3$5T*NQPSUBOUMZIPXFWFSBTBMTPEFUBJMFEJO
Table 4, all medications were associated with significant side effects.
 
Table 4: Medication Outcomes at Post-test  
Side effects* and discontinuation rates
32%  Any extrapyramidal symptom (movement problems 
         including muscle spasms, rigidity + tremors ) 
29%  Decreased prolactin (hormonal change) 
23%  Drowsiness 
20%  Extrapyramidal disorder (characterized by changes in 
         muscle tone + movement) 
6%    Discontinued due to adverse events 
49%  Drowsiness, sedation + excessive sleep 
22%  Oral numbness + taste distortions 
6%  Discontinued due to adverse events 
Thirst  
Excessive urination 
Nausea/vomiting
Dizziness
45%  Nausea
43%  Vomiting 
32%  Tremor
28%  Diarrhea
28%  Excessive thirst
26%  Frequent urination
23%  Dizziness
17%  Elevated thyroid-stimulating hormone (hormonal change)
0%  Discontinued due to adverse events‡
80%  Sedation
47%  Gastrointestinal irritation
47%  Headache
47%  Increased prolactin (hormonal change) 
33%  Dizziness
33%  Dry mouth
27%  Nausea/vomiting
0%    Discontinued due to adverse events
50%  Drowsiness
39%  Headache
24%  Fatigue
12%  Discontinued due to adverse events
 
Outcomes 
È	Bipolar disorder severity
È	Manic symptoms (3 of 3)
È	Manic severity 
È	Depressive symptoms (1 of 3)** 
  Depressive severity
È	Problems with overall functioning
  Quality of life 
È	Bipolar disorder severity
È	Manic symptoms 
  Manic + depressive symptoms
È	Problems with overall functioning 
 
È	Manic symptoms (2 of 2)
  Manic severity
  Depressive symptoms
  Problems with overall functioning 
 
 
 
 
È	Manic symptoms
  Depressive symptoms
  Problems with overall functioning 
 
 
 
 
È	Bipolar disorder severity
È	Manic symptoms
  Depressive symptoms
Medication 
Aripiprazole 6
 
 
 
 
 
 
Asenapine 7
 
 
Lithium I 8
 
 
 
Lithium II 9
 
 
 
 
 
 
 
 
Quetiapine† 10
 
 
 
 
 
 
 
Risperidone 11
All four side effects were experienced by 
significantly more youth on lithium than 
placebo. Authors did not report the percentage 
of young people experiencing them nor the 
discontinuation rate.
* Experienced by ≥20% of those on medication, or by significantly more in the intervention group  
for studies that appropriately tested for statistical significance.
È	Statistically significant improvements for medication over placebo.
** Statistically significant for 10 mg dose but not 30 mg.
  No statistically significant difference between medication and placebo.
† Those in both quetiapine and placebo groups were given divalproex as the primary medication.
‡ Although 11.3% of participants stopped taking lithium, study authors did not deem discontinuation as being due to adverse events. 
 
Psychosocial intervention outcomes
&BDIPGUIFOFXQTZDIPTPDJBMJOUFSWFOUJPOTTIPXFECFOFëUTBMCFJUNJYFEPSNPEFTUJOTPNFDBTFT'PS
.VMUJGBNJMZ1TZDIPFEVDBUJPOBM1TZDIPUIFSBQZBUNPOUIGPMMPXVQNBOJBBOEEFQSFTTJWFTZNQUPNT
	BTTFTTFEJOBTJOHMFNFBTVSF
XFSFTJHOJëDBOUMZMFTTTFWFSFGPSJOUFSWFOUJPOQBSUJDJQBOUTDPNQBSFEXJUI
controls.12
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$IJMEBOE'BNJMZ'PDVTFE$#5BUQPTUUFTUTIPXFENJYFEPVUDPNFTXJUIOPEJêFSFODFTSFHBSEJOH
bipolar severity or manic symptoms for intervention participants compared with controls.13 However, 
EFQSFTTJWFTZNQUPNTEFDSFBTFEBDDPSEJOHUPQBSFOUSBUJOHT	BMUIPVHIOPUQSBDUJUJPOFSSBUJOHT
"TΉXFMM
JOUFSWFOUJPOQBSUJDJQBOUTIBETJHOJëDBOUMZIJHIFSPWFSBMMGVODUJPOJOHUIBODPOUSPMT	$POUSPMZPVUIOPUBCMZ
received 18 unstructured therapy sessions for bipolar symptoms, a relatively intensive level of control 
JOUFSWFOUJPOUIBUNBZIBWFBêFDUFEUIFëOEJOHT
13
'BNJMZ'PDVTFEɨFSBQZΉ*BMTPTIPXFENJYFEPVUDPNFT'PSUJNFTQFOUGSFFPGTJHOJëDBOUmanic/
hypomanic symptoms, no significant differences were reported between intervention and 
DPOUSPMHSPVQTPWFSUIFUXPZFBSTUVEZQFSJPE)PXFWFSGPSUJNFTQFOUGSFFPGQSPNJOFOU
depressiveTZNQUPNTUIFJOUFSWFOUJPOHSPVQEJECFUUFSUIBODPOUSPMT	WTΉXFFLT
14
'PS'BNJMZ'PDVTFEɨFSBQZΉ**JOUFSWFOUJPOZPVUIFYQFSJFODFETJHOJëDBOUMZGFXFS
weeks of prominent manic, hypomanic and depressive symptoms compared with controls. 
4QFDJëDBMMZPWFSUIFPOFZFBSTUVEZQFSJPEJOUFSWFOUJPOZPVUIXFSFGSFFPGNPPETZNQUPNT
for 26.8 weeks, versus 19.5 for controls.15
*ODPOUSBTU'BNJMZ'PDVTFEɨFSBQZΉ***QSPEVDFEOPCFOFëDJBMPVUDPNFTSFMBUFEUP
bipolar disorder.16 Specifically, intervention and control participants did not differ in the number of weeks 
JUUPPLUIFNUPSFDPWFSGSPNNBOJDPSEFQSFTTJWFTZNQUPNTPWFSUIFUXPZFBSTUVEZQFSJPE	3FDPWFSZXBT
EFëOFEBTFYQFSJFODJOHBUMFBTUFJHIUDPOTFDVUJWFXFFLTXJUIOPNPSFUIBONJOPSNPPETZNQUPNT
5BCMFΉ
TVNNBSJ[FTUIFPVUDPNFTGPSBMMëWFQTZDIPTPDJBM3$5T
 
Table 5: Psychosocial Intervention Outcomes* 
Outcomes
È	Manic + depressive symptom severity
  Bipolar disorder severity
  Manic symptoms 
È	Depressive symptoms (1 of 2)
È	Problems with overall functioning
  # of weeks with prominent manic/hypomanic symptoms
È	# of weeks with prominent depressive symptoms 
È	# of weeks with prominent manic, hypomanic or depressive symptoms
  # of weeks until recovery from manic/hypomanic symptoms 
  # of weeks until recovery from depressive symptoms 
Follow-up
10 months
 
Post-test
 
 
 
15 months**
 
8 months**
 
15 months**
Program
Multifamily Psychoeducational 
Psychotherapy (MF-PEP) 12
Child- and Family-Focused 
Cognitive-Behavioural 
Therapy (CFF-CBT) 13
 
Family-Focused Therapy I 14
 
Family-Focused Therapy II 15
 
Family-Focused Therapy III 16
* Majority of participating youth were also taking medications to treat their bipolar disorder.
È	Statistically significant improvements for intervention over comparison.
  No statistically significant difference between intervention and comparison.
** Rather than being assessed solely at follow-up, outcomes were evaluated over the entire study duration. 
 
Dietary supplement outcomes
The only dietary supplement trial that met our 
inclusion criteria failed to show benefits. As shown 
JO5BCMFΉìBYPJMEJEOPUTJHOJëDBOUMZEJêFS
GSPNPMJWFPJM	UIFQMBDFCP
GPSBOZCJQPMBSSFMBUFE
PVUDPNFBUQPTUUFTU17
 
Table 6: Dietary Supplement Outcomes at Post-test 
Outcomes
  Bipolar disorder severity
  Manic symptoms
  Depressive symptoms
  Problems with overall functioning 
Supplement
Flax oil 17
  No statistically significant difference for flax oil over placebo. 
 
The only dietary 
supplement trial 
that met our 
inclusion criteria 
failed to show 
benefits.
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 Medications 
can dramatically 
reduce symptoms 
and improve 
young people’s 
functioning.
There are effective treatments
Our review affirms that there are effective treatments for bipolar disorder. Among the medications, 
aripiprazole and lithium stood out. Aripiprazole significantly reduced the severity of bipolar disorder in 
general and reduced manic symptoms in particular. It also improved overall functioning.6 And lithium 
reduced manic symptoms while improving overall functioning.8–9 Health Canada has also approved both 
these medications for treating bipolar disorder in youth.18 Still, both medications have significant side effects, 
outlined in Table 4, and therefore require close monitoring when prescribed.6, 8–9, 14–15 Although the other three 
NFEJDBUJPOTΉBTFOBQJOFRVFUJBQJOF	BEKVODUJWFUPEJWBMQSPFY
BOESJTQFSJEPOFΉTIPXFE
some benefits, they are not approved by Health Canada for treating bipolar disorder in young 
people. They also led to significant side effects.
Our review also found research evidence on new psychosocial treatments with 
considerable promise for young people with bipolar disorder. These interventions were 
delivered in the community and were relatively brief, ranging from 12 to 21 sessions over 
two to nine months — qualities likely making them appealing to youth and families. As well, 
FBDIQSPHSBNIBENVMUJQMFCFOFëUT.'1&1SFEVDFECPUINBOJDBOEEFQSFTTJWFTZNQUPN
severity.12$''$#5SFEVDFEEFQSFTTJWFTZNQUPNTBOEJNQSPWFEPWFSBMMGVODUJPOJOH13 
"OE'BNJMZ'PDVTFEɨFSBQZEFDSFBTFEUIFEVSBUJPOPGEFQSFTTJPOJOPOFTUVEZBOEEFDSFBTFEUIFEVSBUJPO
of manic, hypomanic and depressive symptoms in another.14–15 While psychosocial interventions were used 
alongside medications in these trials, our findings suggest important added benefits for young people over 
medications alone — particularly in addressing depressive symptoms.
ɨFPOF3$5POBEJFUBSZTVQQMFNFOUTIPXFEUIBUìBYPJMXBTOPUIFMQGVMJOUSFBUJOHCJQPMBSEJTPSEFS 
in young people.17 This supplement is therefore not recommended.
Implications for practice and policy
3FTFBSDIFSTIBWFNBEFQSPHSFTTPWFSUIFQBTUΉZFBSTJOJEFOUJGZJOHJOUFSWFOUJPOTUPIFMQZPVOHQFPQMF
XJUICJQPMBSEJTPSEFS8IJMFNPSF3$5TBSFOFFEFEQBSUJDVMBSMZPONFEJDBUJPOTBOEUIFJSTJEFFêFDUTOFX
psychosocial interventions show considerable promise alongside medications. Our findings suggest five 
JNQMJDBUJPOTGPSQSBDUJUJPOFSTBOEQPMJDZNBLFST
É 1SPWJEFMPOHUFSNTVQQPSUT#JQPMBSEJTPSEFSJTBMPOHUFSNDPOEJUJPO8IJMFJUNBZXBYBOEXBOF
young people with this disorder still need intensive and comprehensive ongoing health, social and other 
supports.
É 6TFNFEJDBUJPOTXJTFMZ Most young people with bipolar disorder will need medication to manage 
UIJTEJTPSEFS1SBDUJUJPOFSTΉJODPMMBCPSBUJPOXJUIZPVOHQFPQMFBOEUIFJSGBNJMJFTOFFEUPDBSFGVMMZ
choose which medication to use. Aripiprazole and lithium should be considered first, given their evidence 
PGFêFDUJWFOFTTBOEUIFJSBQQSPWBMCZ)FBMUI$BOBEB	8IJMFBTFOBQJOFSJTQFSJEPOFBOERVFUJBQJOF
adjunctive to divalproex, also reduced manic symptoms, Health Canada has not approved these 
NFEJDBUJPOTGPSUSFBUJOHCJQPMBSEJTPSEFSJOQFPQMFZPVOHFSUIBOΉ
1SBDUJUJPOFSTXIPQSFTDSJCFBOZ
medications must carefully monitor the responses and also the emergence of side effects, so these, too, can 
be managed. As well, using lowest possible doses to achieve good clinical effects can help to minimize side 
effects. Minimizing side effects can also help to reduce the high rates of young people with bipolar disorder 
who stop their medications because of side effects. Beyond this, new research is needed that does not have 
pharmaceutical company funding and involvement.
É 0GGFSQTZDIPTPDJBMUSFBUNFOUBTXFMMBTNFEJDBUJPO The three effective psychosocial treatments 
provided education about bipolar disorder and taught youth and their parents skills for managing 
mood symptoms, solving problems and communicating better. While more research is needed, these 
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interventions still show much promise and could be implemented now. Once a young person’s symptoms 
are stable enough for them to participate in a psychosocial intervention, practitioners can be guided by 
the presenting concerns in deciding which one to suggest. CFF-CBT is most likely to help with managing 
depression, while MF-PEP and Family-Focused Therapy are most likely to help with managing both 
mania and depression.
É 4VQQPSUQSBDUJUJPOFSTUPPGGFSFGGFDUJWFQTZDIPTPDJBMUSFBUNFOUT Because the effective psychosocial 
treatments have only recently been evaluated for treatment of bipolar disorder, their availability is likely 
limited. For this reason, policy-makers may need to provide supports for practitioners to learn these 
interventions. To facilitate this process, the developers of the psychosocial treatments have published books 
describing the interventions.22–24
É %JTDPVSBHFJOFGGFDUJWFJOUFSWFOUJPOT Some young people and their families prefer not to use 
medications to treat bipolar disorder and seek other options. This reaction is understandable, particularly 
given the negative side effects and the fact that medications need to be used long term. Yet the only dietary 
supplement studied that met our criteria — flax oil — was not effective. Anyone expressing an interest 
in dietary supplements should be given this information. As well, Health Canada needs to ensure that 
companies marketing and selling these products do not make misleading or unproven claims about their 
effectiveness — and that potential harms are also carefully assessed, as with any drug.
Receiving a bipolar diagnosis can cause much stress and apprehension for young people and for their 
families — understandably, given the potential severity of the symptoms as well as the long-term nature of 
the condition. As well, all of the medications recommended to treat bipolar disorder have side effects. Still, 
medications can dramatically reduce symptoms and improve young people’s functioning. Also, positive results 
from trials of new psychosocial treatments give reason for hope. Young people and their families should be 
given the message that bipolar disorder can be managed — and that many people with this disorder have gone 
on to thrive and to make important contributions, according to their abilities and gifts.
rev iew
What are the medication options for depressive episodes?
Depression is often part of bipolar disorder in young people — and it can be particularly severe. While psychosocial treatments such as cognitive-behavioural therapy (CBT) are effective, 
engaging in CBT can be difficult when bipolar symptoms (including depression) are particularly 
acute or intense. At the same time, typical antidepressant medications can make bipolar disorder 
worse.20 Therefore, medications options are needed for young people with bipolar disorder who 
have depression. 
Researchers recently evaluated the medication lurasidone as a treatment for depression 
among youth with bipolar disorder.21 Researchers conducted a six-week randomized controlled 
trial (RCT) including 350 young people from 11 countries. (This RCT did not meet criteria for 
our review because it did not assess manic or hypomanic outcomes. Like many studies in our 
review, the drug company provided funding and some research staff for the study.) This RCT 
found that for young people with bipolar disorder, lurasidone led to significantly fewer depressive 
symptoms than controls, with a moderate clinical impact (Cohen’s d = 0.45). Side effects were 
common, with 64% of participants reporting at least one. Health Canada has approved the use 
of lurasidone for 13- to 17-year-olds who have bipolar disorder and experience a depressive 
episode — providing a new treatment option.18
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We use systematic review methods adapted from the Cochrane Collaboration and Evidence-Based Mental Health. We build quality assessment into our inclusion criteria to ensure that we report on the best available evidence — requiring that intervention studies use randomized controlled 
trial 	3$5
NFUIPETBOEBMTPNFFUBEEJUJPOBMRVBMJUZJOEJDBUPST'PSUIJTSFWJFXXFTFBSDIFEGPS3$5TPO
interventions that aimed to help youth with bipolar disorder. Table 7 outlines our database search strategy.
5PJEFOUJGZBEEJUJPOBM3$5TXFBMTPIBOETFBSDIFESFGFSFODFMJTUTGSPNSFMFWBOUQVCMJTIFETZTUFNBUJD
SFWJFXTBOEGSPNQSFWJPVT$IJMESFOT)FBMUI1PMJDZ$FOUSFQVCMJDBUJPOT6TJOHUIJTBQQSPBDIXFJEFOUJëFE
50 studies published in the past 20 years. Two team members then independently assessed each study, 
applying the inclusion criteria outlined in Table 8.
For more information on our research methods, please contact
Jen Barican, chpc_quarterly@sfu.ca 
$IJMESFOT)FBMUI1PMJDZ$FOUSF'BDVMUZPG)FBMUI4DJFODFT 
4JNPO'SBTFS6OJWFSTJUZ3PPN8FTU)BTUJOHT4U7BODPVWFS#$7#,
M E T H O D S
É $BNQCFMM$PDISBOF$*/")-&3*$.FEMJOFBOE1TZD*/'0
É #JQPMBSand treatment  
É 1FFSSFWJFXFEBSUJDMFTQVCMJTIFEJO&OHMJTICFUXFFOBOE
É 1FSUBJOJOHUPDIJMESFOBHFEZFBSTPSZPVOHFS
É 4ZTUFNBUJDSFWJFXNFUBBOBMZTJTPS3$5NFUIPETVTFE
Table 7: Search Strategy
Sources
Search Terms
Limits
Table 8: Inclusion Criteria for RCTs 
É 1BSUJDJQBOUTXFSFSBOEPNMZBTTJHOFEUPJOUFSWFOUJPOBOEDPOUSPMHSPVQT
É 4UVEJFTQSPWJEFEDMFBSEFTDSJQUJPOTPGQBSUJDJQBOUDIBSBDUFSJTUJDTTFUUJOHTBOEJOUFSWFOUJPOT
É *OUFSWFOUJPOTBJNFEUPUSFBUCJQPMBSEJTPSEFSBNPOHZPVOHQFPQMF
É *OUFSWFOUJPOTXFSFFWBMVBUFEJOTFUUJOHTUIBUXFSFBQQMJDBCMFUP$BOBEJBOQPMJDZBOEQSBDUJDF
É "UTUVEZPVUTFUNPSFUIBOPGQBSUJDJQBOUTIBEBCJQPMBSEJTPSEFSEJBHOPTJT
É "UUSJUJPOSBUFTXFSFPSMFTTBUGJOBMBTTFTTNFOUBOEPSJOUFOUJPOUPUSFBUBOBMZTJTXBTVTFE
É $IJMENFOUBMIFBMUIJOEJDBUPSTJODMVEFENBOJDPSIZQPNBOJDTZNQUPNT
É .FEJDBUJPOTUVEJFTVTFEEPVCMFCMJOEJOHQSPDFEVSFTBOEQMBDFCPDPOUSPMT
É 1TZDIPTPDJBMTUVEJFTIBEBUMFBTUPOFPVUDPNFSBUFSCMJOEFEUPQBSUJDJQBOUT¼HSPVQBTTJHONFOU
É 4UVEJFTEPDVNFOUFESFMJBCJMJUZBOEWBMJEJUZPGBMMQSJNBSZPVUDPNFNFBTVSFT
É 4UVEJFTSFQPSUFEMFWFMTPGTUBUJTUJDBMTJHOJGJDBODFGPSQSJNBSZPVUDPNFNFBTVSFT
É 4JEFFGGFDUTBOEBEWFSTFSFBDUJPOTXFSFDPNQSFIFOTJWFMZBTTFTTFEBOESFQPSUFEGPSNFEJDBUJPOT
É 4UVEJFTPVUDPNFTXFSFFYDMVEFEXIFOUIFSFXBTJOTVGGJDJFOUTUBUJTUJDBMQPXFSPSJOBQQSPQSJBUF
analyses*
* We defined inappropriate statistical analyses as those that did not control for multiple comparisons and/or variables that 
might influence the outcome of interest.
 
5XFMWF3$5TNFUBMMUIFJODMVTJPODSJUFSJB'JHVSFΉBEBQUFEGSPN1SFGFSSFE3FQPSUJOH*UFNTGPS
4ZTUFNBUJD3FWJFXTBOE.FUB"OBMZTFT	13*4."
EFQJDUTPVSTFBSDIQSPDFTT%BUBGSPNUIFTFTUVEJFTXFSF
then extracted, summarized and verified by two or more team members. Throughout our process,  
any differences between team members were resolved by consensus.  
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methods
Records identified through
database searching
(n = 675)
Records identified through
hand-searching
(n = 15)
Records excluded after
title screening
(n = 291)
Abstracts excluded
(n = 320)
Full-text articles excluded
(n = 38 studies
[49 articles])
Total records screened (n = 690)
Abstracts screened for relevance
(n = 399)
Full-text articles assessed
for eligibility
(n = 50 studies [79 articles])
Studies included in review
(n = 12 studies [30 articles])
Figure 1: Search Process for RCTs
Id
en
ti
fi
ca
ti
on
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
ud
ed
Chi ldren ’s  Menta l  Heal th  Research Quar ter ly  Vol .  13 ,  No.  1    15    © 2019 Children’s Health Policy Centre, Simon Fraser University
TPCFTUIFMQDIJMESFOQSBDUJUJPOFSTBOEQPMJDZNBLFSTOFFEHPPEFWJEFODFPOXIFUIFSPSOPUBHJWFOintervention works. Randomized controlled trials	3$5T
BSFUIFHPMETUBOEBSEGPSBTTFTTJOHXIFUIFSBOJOUFSWFOUJPOJTFêFDUJWF*OΉ3$5TDIJMESFOBSFSBOEPNMZBTTJHOFEUPUIFJOUFSWFOUJPO
group or to a comparison or control group. By randomizing participants — that is, giving every child an equal 
likelihood of being assigned to a given group — researchers can help ensure the only difference between the 
groups is the intervention. This process provides confidence that benefits are due to the intervention rather 
than to chance or other factors. 
Then, to determine whether the intervention actually provides benefits to children, researchers analyze key 
outcomes. If an outcome is found to be statistically significant, it helps provide certainty the intervention 
was effective rather than it appearing that way due to a random error. In the studies we reviewed, researchers 
set a value enabling at least 95% confidence that the observed results are real. 
Once an intervention has been found to have a statistically significant benefit, it is helpful to quantify the 
degree of difference it made, or its effect size. Beyond identifying that the intervention works, an effect size 
indicates how much of a clinically meaningful difference the intervention made in children’s lives. Cohen’s d 
XBTUIFFêFDUTJ[FNFBTVSFSFQPSUFEJOUIJTJTTVF7BMVFTDBOSBOHFGSPNUPΉ4UBOEBSEJOUFSQSFUBUJPOTBSF
ΉΉTNBMMFêFDUΉΉNFEJVNFêFDUΉΉMBSHFFêFDU  
R E S E A R C H T E R M S E X P L A I N E D
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R E F E R E N C E S
BC government staff can access original articles from 
BC’s Health and Human Services Library. Articles 
NBSLFEXJUIBOΉBTUFSJTLΉ	
JODMVEFSBOEPNJ[FE
DPOUSPMMFEUSJBMEBUBUIBUXBTGFBUVSFEJOPVS3FWJFX
article.
1. "NFSJDBO1TZDIJBUSJD"TTPDJBUJPO	

Diagnostic and statistical manual of mental 
disorders: DSM-5	UIΉFE
8BTIJOHUPO%$
"NFSJDBO1TZDIJBUSJD"TTPDJBUJPO
2. 8PSME)FBMUI0SHBOJ[BUJPO	

International classification of diseases and related 
health problems: ICD-11	UIΉSFW
3FUSJFWFE
GSPNIUUQTJDEXIPJOU
3. 1BSFOT&+PIOTUPO+	
$POUSPWFSTJFT
concerning the diagnosis and treatment 
of bipolar disorder in children. Child and 
Adolescent Psychiatry and Mental Health, 4, 
1–14. 
4. 7BO.FUFS"3#VSLF$,PXBUDI 
3"'JOEMJOH3Ή-:PVOHTUSPN&Ή"
	
5FOZFBSVQEBUFENFUBBOBMZTJTPGUIF
clinical characteristics of pediatric mania and 
hypomania. Bipolar Disorders, 18, 19–32. 
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